Blog

BBK Worldwide Featured in Newly Published Innovations in Pharmaceutical Development™

Guide Provides In-Depth Profiles of World’s Most Disruptive Pharma Services Innovators

BBK Worldwide has been recognized as a top innovator in Innovations in Pharmaceutical Development™. This newly published guide highlights the companies and thought leaders at the forefront of innovation in the pharmaceutical development space. 

Earlier this week, Elizabeth Gargill went one-on-one with Outsourcing-Pharma, discussing findings from BBK's recent Study Voices survey that reveal shifts in healthcare consumer attitudes and behaviors since the onset of COVID-19. In this in-depth interview, Elizabeth discusses why clinical trial innovation is more important now than ever before and how clinical trial sponsors can leverage the survey findings to enhance their enrollment and engagement efforts.

Clinical trial sponsors now have access to several new solutions that make it possible to engage with patients wherever they are — now more important than ever before as trials shift to hybrid and decentralized models.

Sponsors can transform their clinical trials with engagement solutions that prioritize patient care and convenience, helping maintain study momentum during COVID-19 and beyond.

Ready, Set, Go Virtual!

New virtual engagement solutions are delivering patients the convenience and immediacy they want in their healthcare experience. Solutions that support decentralized or hybrid trials, like BBK’s virtual RSG^® Card, are helping to remove some of the barriers to clinical trial participation that patients cite as the most challenging.

As a matter of fact, in BBK's recent Study Voices 2020 survey, patients selected "immediate reimbursement for study-related expenses" as the most important solution influencing their decision to participate in a clinical trial.

During the last two weeks of August we surveyed more than 1,200 healthcare consumers, medical professionals, and members of the pharmaceutical industry for their perspectives on topics impacting today's healthcare consumer.

The findings provide a unique look at current attitudes and behaviors that inform the patient experience. They provide clinical trial sponsors with a snapshot of a critical moment in time when we're seeing the rise of telehealth, the adoption of decentralized and hybrid trials, and heightened awareness of clinical research. They also reveal new opportunities and challenges ahead for clinical trial enrollment and engagement.

DPharm. It's one of my favorite conferences that I look forward to each year. This year we will be virtual September 22-23, but still the same great energy and excitement. DPharm is a standout event that challenges and reports on innovation, with the goal of shaking up the way we conduct clinical trials so that we can reduce patient / physician burden and create greater efficiencies.

Rapid Adoption of Patient-centric Innovation Seen as Positive Outcome of COVID-19 Research Collaborations

While COVID-19 has severely affected many industries, scientific pursuit for a host of medical conditions is also threatened by sharply negative effects of the pandemic on clinical research for non-COVID-19-related pursuits. This is evidenced by an industry-reported 65 percent decline in new patient study enrollment in March 2020 relative to March 2019. The industry is adapting by borrowing from the zealous approach associated with COVID-19 research by deploying extraordinary collaboration and patient-centric services to achieve timelines for as many studies as possible.

For clinical trial sponsors, staying on top of the latest innovations can be a challenge, especially in an industry historically slow to adapt to change. But experts warn of the risk of falling behind, especially in light of advancing technologies that are impacting clinical trial enrollment and engagement.

While you may not be ready to embrace the use of a virtual self-service hologram—greeting patients in the doctor’s office with information about a clinical trial—there are a few key innovations that all clinical trial sponsors should keep on their radar. Below, we highlight three that are driving significant change.